bioRxivMicrobiology
Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo
A. Schaefer, F. Muecksch, J. C. C. Lorenzi, S. R. Leist, M. Cipolla, S. Bournazos, F. Schmidt, A. Gazumyan, R. S. Baric, D. F. Robbiani, T. Hatziioannou, J. V. Ravetch, P. D. Bieniasz, M. C. Nussenzweig, T. P. Sheahan
Abstract
SARS-CoV-2, the causative agent of COVID-19, is responsible for over 24 million infections and 800,000 deaths since its emergence in December 2019. There are few therapeutic options and no approved vaccines. Here we examine the properties of highly potent human monoclonal antibodies (hu-mAbs) in a mouse adapted model of SARS-CoV-2 infection (SARS-CoV-2 MA). In vitro antibody neutralization potency did not uniformly correlate with in vivo activity, and some hu-mAbs were more potent in combination in vivo. Analysis of antibody Fc regions revealed that binding to activating Fc receptors is essential for optimal protection against SARS-CoV-2 MA. The data indicate that hu-mAb protective activity is dependent on intact effector function and that in vivo testing is required to establish optimal hu-mAb combinations for COVID-19 prevention.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection
E. S. Winkler, P. Gilchuk, … M. Diamond·bioRxiv·Dec 28, 2020
- Fc-independent neutralization of SARS-CoV-2 by recombinant human monoclonal antibodies
T. Noy-Porat, A. Edri, … O. Mazor·bioRxiv·May 15, 2021
- A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques
R. R. Cobb, J. Nkolola, … J. E. Crowe·bioRxiv·Sep 27, 2021
- Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions
C. N. Pierre, L. E. Adams, … K. Saunders·bioRxiv·Jul 25, 2023
- Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals
S. J. Zost, P. Gilchuk, … J. E. Crowe·bioRxiv·May 22, 2020
- A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model
J. Kreye, S. M. Reincke, … N. Osterrieder·bioRxiv·Aug 15, 2020